Enanta reports Q2 net loss of $33.6M; revenue down to $18.7M on lower HCV royalties

ENANTA PHARMACEUTICALS INC

2022-Q2 EPS reported -$3.11 revenue$46,364,000

Net loss of $33.6M ($1.63/share) vs. loss of $22.0M ($1.09/share) last year.
Total revenue of $18.7M, down 7% YoY, all royalty from AbbVie's HCV regimen MAVYRET.
Cash and securities $322.5M; expects to fund operations for at least two years.
Expects topline data from RSVP Phase 2b study of EDP-938 in adults with RSV this quarter.
FDA Fast Track for EDP-235 (COVID-19); preliminary Phase 1 data expected this quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.